ESSENTIAL WORKUP
- Emergent head CT (noncontrast) to evaluate for hemorrhage (parenchymal, subarachnoid, traumatic), large acute infarcts, prior pathology
- Thorough neurologic and cardiac exam
- Neurology consultation
- 12-lead ECG for arrhythmias and myocardial ischemia
- CTA and/or MRA for imaging of the posterior circulation
DIAGNOSIS TESTS & NTERPRETATION
Lab
- CBC:
- Anemia, thrombocytopenia; polycythemia, thrombocytosis
- Coagulation studies (PT/PTT):
- Hypo- and hypercoagulable states; baseline values for anticoagulant and fibrinolytic therapies
- Electrolytes, BUN/creatinine, glucose
- Cardiac markers for concurrent myocardial ischemia
- Urinalysis
- ESR for systemic vasculitides
- Rapid plasma reagin
- Thyroid stimulating hormone
- Lipid profile
Imaging
- Emergent head CT (noncontrast)
- Head and neck CT angiogram (CTA) for evaluation of posterior circulation and possible acute vascular intervention
- Chest radiograph; consider chest CTA for cardiopulmonary and great vessel pathology
- MRI/magnetic resonance angiography (MRA) for improved characterization of ischemic lesion and cerebrovascular circulation (e.g., congenital VB anomalies, exclusion of VA dissection)
- Echocardiography for intracardiac embolic source
- Cervical Doppler US
- Transcranial Doppler US
Diagnostic Procedures/Surgery
- Neuroangiography for diagnosis
- Directed intra-arterial thrombolytic therapy/angioplasty/stenting/embolectomy are still under investigation)
DIFFERENTIAL DIAGNOSIS
- CNS:
- CVA (hemorrhagic or ischemic):
- Cerebral
- Cerebellar
- Brainstem
- Multiple sclerosis
- Migraine syndromes
- Seizure (focal)
- Traumatic injury/postconcussive
- Tumor
- Vascular malformation hemorrhage (arteriovenous malformation, subarachnoid)
- Brainstem herniation
- Peripheral nervous system:
- Ear, nose, throat:
- Cerebellopontine angle tumor
- Ear canal pathology (foreign body, tumor)
- Labyrinthitis/otitis media
- Ménière disease
- Benign paroxysmal positional vertigo
- Cardiovascular:
- Arrhythmia
- Myocardial ischemia/infarct
- Aneurysm/dissection (VA, basilar artery, subclavian artery, aorta)
- Hypovolemia
- Vasculitides
- Endocrine:
- Adrenal insufficiency
- Hypothyroidism
- Hematologic:
- Anemia
- Coagulopathy/hypercoagulable state
- Infectious:
- Encephalitis/meningitis
- Otitis media/mastoiditis
- Septic shock
- Syphilis
- Metabolic:
- Hypoglycemia; hyperglycemia
- Electrolyte imbalance
- Toxicologic:
- Ataxia: Alcohols, lithium, phenytoin
- Salicylism
- Serotonin syndrome
- Iatrogenic
TREATMENT
PRE HOSPITAL
- ABCs
- Fingerstick glucose measurement
- Naloxone if indicated
- Notification:
- Urgent contact with receiving facility if airway compromise or hemodynamic instability
INITIAL STABILIZATION/THERAPY
- ABCs
- Administer oxygen
- Place on cardiac monitor and pulse oximeter
- Establish IV access with 0.9% normal saline
ED TREATMENT/PROCEDURES
- Cerebrovascular perfusion management:
- Supportive care
- Supine position
- Antiplatelet agent if no hemorrhagic source
- Anticoagulation:
- Consider in consultation with neurology if significant risk factors for embolic source, unstable or progressive ischemic symptoms
- Ideal BP targets not well defined; maintain BPs within patient’s expected range (i.e., account for chronic hypertension)
- If hypotensive: Fluid resuscitation; vasopressors or blood as indicated
- If hypertensive: Administer titratable antihypertensive medications for severe HTN (mean arterial pressure >140 mm Hg, systolic BP >220 mm Hg, diastolic BP >130 mm Hg) or hemorrhage/aneurysm/dissection, myocardial or other end-organ dysfunction
- GI:
- NPO (rehydrate with IV fluids; maintain normoglycemia)
- Antiemetics
- Consultation:
- Neurology
- Vascular interventional radiology for neuroangiography
MEDICATION
- Aspirin: 325 mg PO
- Clopidogrel: 75 mg PO
- Warfarin (dose for atrial fibrillation): 2–5 mg PO loading dose
- Heparin (dose for atrial fibrillation): 50–60 U/kg IV bolus, then IV infusion at 12–18 U/kg for target PTT 50–70 sec
- Labetalol: 20–40 mg IV over 2 min, then 40–80 mg IV q10min (max. 300 mg IV)
- Meclizine: 25 mg PO q8–12h
- Naloxone: 0.4–2 mg IM/IV q2–3min PRN
- Nitroprusside: 0.25–10 μg/kg/min IV infusion (max. 10 μg/kg/min)
- Ondansetron: 4 mg IV
- Promethazine: 12.5–25 mg PO/PR/IV q6–8h
- Ticlopidine: 250 mg PO BID
FOLLOW-UP
DISPOSITION
Admission Criteria
- ICU admission for:
- Altered mental status with airway issues
- Concurrent hemodynamic instability
- Malignant cardiac arrhythmias
- Admit to hospital to identify or exclude etiologies of VB ischemia and to prevent recurrence or progression to VB circulation cerebrovascular accident, especially in the following populations:
- Elderly
- Inability to ambulate
- Inability to tolerate oral intake
- Inability to arrange (expeditious) outpatient follow-up
- New or changing neurologic deficit
- Persistent dizziness
- Syncope
- Vascular risk factors
Discharge Criteria
- Consider discharge with outpatient follow-up in populations with the following:
- None of above indications to consider admission
- Alternative explanation for symptomatology
Issues for Referral
- VB ischemia-related referrals as arranged/recommended by admitting team
- Arrange expeditious referrals with PCP or appropriate specialist (e.g., neurology, otorhinolaryngology, vascular surgery) as indicated for alternative explanation for symptomatology
FOLLOW-UP RECOMMENDATIONS
- VB ischemia-related follow-up as arranged/recommended by admitting team
- Urgency and nature of other follow-up as determined by alternative explanation of symptomatology
PEARLS AND PITFALLS
- Always consider VB insufficiency for dizziness, vertigo, mental status changes, syncope, and overlapping/atypical neurologic presentations
- VBI more likely to occur in patients with spontaneous vertigo lasting a few minutes with accompanying neurologic symptoms and who have cardiovascular risk factors
- Start antithrombotic/antiembolic treatments for VB insufficiency in the absence of contraindications
ADDITIONAL READING
- Ishiyama G, Ishiyama A. Vertebrobasilar infarcts and ischemia.
Otolaryngol Clin North Am
. 2011;44:415–435.
- Love BB, Biller J. Neurovascular system. In: CG Goetz, ed.
Textbook of Clinical Neurology.
3rd ed. Philadelphia, PA: Elsevier; 2007:405–434.
- Marquardt L, Kuker W, Chandratheva A, et al. Incidence and prognosis of > or = 50%
symptomatic vertebral or basilar artery stenosis: Prospective population-based study.
Brain
. 2009;132:982–988.
- Savitz SI, Caplan LR. Vertebrobasilar disease.
N Engl J Med
. 2005;352:2618–2626.
- Schneider JI, Olshaker JS. Vertigo, vertebrobasilar disease, and posterior circulation ischemic stroke.
Emerg Med Clin North Am
. 2012;30:681–693.
CODES
ICD9
435.3 Vertebrobasilar artery syndrome
ICD10
G45.0 Vertebro-basilar artery syndrome
VERTIGO
William E. Baker
BASICS
DESCRIPTION
- Dizziness, 3–4% of ED visits, difficult symptom to diagnose, describes a variety of experiences, including:
- Vertigo
- Weakness, fainting
- Lightheadedness
- Unsteadiness
- Vertigo, a hallucination of movement:
- Spinning or turning
- Sensation of movement between the patient and the environment
- Oscillopsia (illusion of an unstable visual world)
- Most patients have an organic etiology.
- Maintenance of equilibrium depends on interaction of 3 systems:
- Visual
- Proprioceptive
- Vestibular
- Any disease that interrupts the integrity of above systems may give rise to vertigo.
- Peripheral vertigo:
- Often, severe symptoms
- Intermittent episodes lasting seconds to minutes, occasionally hours
- Horizontal or horizontal–torsional nystagmus (also positional, fatigues, and suppressed by fixation)
- Normal neurologic exam
- Sometimes associated hearing loss or tinnitus
- Central vertigo:
- Usually mild continuous symptoms
- All varieties of nystagmus (horizontal, vertical, rotatory)
- No positional association
- Presence of neurologic findings most of the time